Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 9/20 | 0.78 |
| ▸ | ERBB2 known ✓ | P04626 | 12/20 | 0.69 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.68 |
| ▸ | KDR known ✓ | P35968 | 3/20 | 0.66 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.66 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.68 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.68 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.68 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.68 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.68 |
| ▸ | ADK | P55263 | 1/20 | 0.68 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.68 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4081444 | 1.00 | EGFR (0.78) | EGFRERBB2EPHA2EPHB4GAK | |
| Hydrochloric Acid SCHEMBL2455816 | 1.00 | EGFR (0.78) | EGFRERBB2EPHA2EPHB4GAK | |
| SCHEMBL3961859 | 0.99 | EGFR (0.79) | EGFRERBB2EPHA2EPHB4GAK | |
| SCHEMBL203146 | 0.99 | EGFR (0.79) | EGFRERBB2EPHA2EPHB4GAK | |
| SCHEMBL31050075 | 0.99 | EGFR (0.79) | EGFRERBB2EPHA2EPHB4GAK | |
| Alcohol SCHEMBL5426837 | 0.96 | EGFR (0.72) | EGFRERBB2EPHA2EPHB4GAK | |
| Hydrochloric Acid SCHEMBL3123628 | 0.95 | EGFR (0.73) | EGFRERBB2EPHA2EPHB4GAK | |
| Hydrochloric Acid SCHEMBL3131145 | 0.95 | EGFR (0.73) | EGFRERBB2EPHA2EPHB4GAK | |
| Hydrochloric Acid SCHEMBL3965089 | 0.95 | EGFR (0.73) | EGFRERBB2EPHA2EPHB4GAK | |
| Hydrochloric Acid SCHEMBL3966746 | 0.95 | EGFR (0.73) | EGFRERBB2EPHA2EPHB4GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303276-B1 | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2013-11-13 | — | — | EP | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8399667-B2 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20120035363-A1 | CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-8088782-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| US-20110237610-A1 | Quinazoline Derivatives as Antiproliferative Agents | ASTRAZENECA AB (SE) | 2011-09-29 | — | — | US | disclosed |
| EP-2303276-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL]OXY}QUINAZOLINE | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-7838530-B2 | Quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| EP-1487806-B1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2010-07-07 | — | — | EP | disclosed |
| US-20060287295-A1 | Quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-7148230-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-12-12 | — | — | US | disclosed |
| EP-1668006-A1 | QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1660479-A1 | PIPERIDYL-QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| US-20050165035-A1 | Quinazoline derivatives | ASTRAZENECA AB | 2005-07-28 | — | — | US | disclosed |
| WO-2005030765-A1 | QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005012290-A1 | PIPERIDYL-QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-02-10 | — | — | WO | disclosed |
| EP-1487806-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | Astrazeneca AB (SE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082831-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ABL1, ERBB2, EGFR | EGFR 3/4885ERBB2 2/4885RET 52/4885 |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885RET 49/4885 |
| US-20060287295-A1 | Quinazoline derivatives as antiproliferative agents | MKI67, CCNI, ERBB2 | EGFR 5/4885ERBB2 3/4885RET 44/4885 |
| US-20110237610-A1 | Quinazoline Derivatives as Antiproliferative Agents | ERBB2, EGFR, MKI67 | EGFR 2/4885ERBB2 1/4885RET 34/4885 |
| US-20050165035-A1 | Quinazoline derivatives | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885RET 13/4885 |
| US-20120035363-A1 | CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... | CDK7, CCNC, CDC73 | EGFR 3132/4885ERBB2 2433/4885RET 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.